Journal
JOURNAL OF IMMUNOLOGY
Volume 183, Issue 8, Pages 4879-4886Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0901531
Keywords
-
Categories
Funding
- Oxford University Clarendon Fund award
- U.K. Medical Research Council [G0601169, G0400808]
- Medical Research Council [G0601169, G0400808] Funding Source: researchfish
- MRC [G0400808, G0601169] Funding Source: UKRI
Ask authors/readers for more resources
The CD200 receptor (CD200R) acts as a negative regulator of myeloid cells by interacting with its widely expressed ligand CD200. Using mutants expressed in U937 cells, we show that inhibition is mediated by the PTB domain binding motif (NPLY) in the receptor's cytoplasmic region. The adaptor protein downstream of tyrosine kinase 2 (Dok2) bound directly to the phosphorylated NPLY motif with a 10-fold higher affinity (K-D of similar to 1 mu M at 37 degrees C) than the closely related Dok1. Both of these proteins have been suggested to play a role in CD200R signaling in marine cells. Dok2 was phosphorylated in response to CD200R engagement and recruited RAS p21 protein activator 1 (RasGAP). Knockdown of Dok2 and RasGAP by RNA interference revealed that these proteins are required for CD200R signaling, while knockdown of Dok1 and the inositol 5-phosphatase SHIP did not affect CD200R-mediated inhibition. We conclude that CD200R inhibits the activation of human myeloid cells through direct recruitment of Dok2 and subsequent activation of RasGAP, which distinguishes this receptor from the majority of inhibitory receptors that utilize ITIMs and recruit phosphatases. The Journal of Immunology, 2009, 183: 4879-4886.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available